Association Between Vascular Endothelial Growth Factor Gene Polymorphisms with Breast Cancer Risk in an Iranian Population

被引:27
作者
Rezaei, Maryam [1 ,2 ]
Hashemi, Mohammad [1 ,2 ]
Sanaei, Sara [2 ]
Mashhadi, Mohammad Ali [3 ]
Taheri, Mohsen [4 ]
机构
[1] Zahedan Univ Med Sci, Cellular & Mol Res Ctr, Zahedan, Iran
[2] Zahedan Univ Med Sci, Sch Med, Dept Clin Biochem, Zahedan, Iran
[3] Zahedan Univ Med Sci, Sch Med, Dept Internal Med, Zahedan, Iran
[4] Zahedan Univ Med Sci, Genet Noncommunicable Dis Res Ctr, Zahedan, Iran
来源
BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2016年 / 10卷
关键词
vascular endothelial growth factor; VEGF; breast cancer; polymorphism;
D O I
10.4137/BCBCR.S39649
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer (BC) is one of the most causes of death in women worldwide. It affects Iranian female population approximately a decade earlier than those in other parts of the world. Previous studies have shown that vascular endothelial growth factor (VEGF) gene variants were associated with BC risk. The current study aimed to evaluate the impact of VEGF rs3025039 (+936C>T), rs2010963 (+405C>G), rs833061 (-460T>C), rs699947 (-2578C>A), and rs35569394 (18-bp I/D) polymorphisms on BC risk in an Iranian population in southeast of Iran. This case-control study was done on 250 BC patients and 215 healthy women. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or PCR was used to genotype the polymorphisms. Our findings showed that VEGF rs699947 variant increased the risk of BC (OR = 1.71, 95% CI = 1.15-2.54, P = 0.009, CA vs CC; OR = 2.12, 95% CI = 1.14-3.93, P = 0.021, AA vs CC; OR = 1.78, 95% CI = 1.22-2.60, P = 0.004, CA+AA vs CC; OR = 1.47, 95% CI = 1.12-1.92, P = 0.005, A vs C). The VEGF rs3025039, rs2010963, rs833061, and rs35569394 variants were not associated with risk/protection of BC. In conclusion, our results proposed that VEGF rs699947 polymorphism may increase the risk of BC development. Furthers studies with larger sample sizes and different ethnicities are necessary to confirm our findings.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 37 条
[1]   Association of a Single-Nucleotide Polymorphism in the Promoter Region of the VEGF Gene with the Risk of Renal Cell Carcinoma [J].
Ajaz, Sadia ;
Khaliq, Shagufta ;
Abid, Aiysha ;
Hassan, Asad Shehzad ;
Hashmi, Altaf ;
Sultan, Gauhar ;
Mohsin, Rehan ;
Mubarrak, Mohammad ;
Naqvi, Syed Ali Anwar ;
Rizvi, Syed Adib-ul-Hasan ;
Mehdi, Syed Qasim .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (09) :653-657
[2]  
Babu GR, 2011, ASIAN PAC J CANCER P, V12, P1647
[3]   Functional vascular endothelial growth factor-2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression [J].
Ben Nasr, Hela ;
Chahed, Karim ;
Bouaouina, Noureddine ;
Chouchane, Lotfi .
CLINICA CHIMICA ACTA, 2008, 395 (1-2) :124-129
[4]   Global estimates of cancer prevalence for 27 sites in the adult population in 2008 [J].
Bray, Freddie ;
Ren, Jian-Song ;
Masuyer, Eric ;
Ferlay, Jacques .
INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (05) :1133-1145
[5]   Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene [J].
Brogan, IJ ;
Khan, N ;
Isaac, K ;
Hutchinson, JA ;
Pravica, V ;
Hutchinson, IV .
HUMAN IMMUNOLOGY, 1999, 60 (12) :1245-1249
[6]   Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update [J].
Chen, Quanchi ;
Zhou, Zifei ;
Shan, Liangcheng ;
Hua, Yingqi ;
Zeng, Hui ;
Liu, Pengcheng ;
Cai, Zhengdong .
BIOMEDICAL REPORTS, 2014, 2 (06) :823-830
[7]   Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer [J].
Eskandari-Nasab, Ebrahim ;
Hashemi, Mohammad ;
Rezaei, Hamzeh ;
Fazaeli, Aliakbar ;
Mashhadi, Mohammad Ali ;
Moghaddam, Simin Sargholzaei ;
Arbabi, Farshid ;
Jahantigh, Mahdi ;
Taheri, Mohsen .
MOLECULAR BIOLOGY REPORTS, 2012, 39 (12) :10531-10539
[8]   VEGF and the quest for tumour angiogenesis factors [J].
Ferrara, N .
NATURE REVIEWS CANCER, 2002, 2 (10) :795-803
[9]   Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].
Ferrara, N .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14
[10]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676